Result card

  • ECO3: What are the unit costs of the resources used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what are the unit costs of the resources used when delivering standard clinical practice?
English

What are the unit costs of the resources used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what are the unit costs of the resources used when delivering standard clinical practice?

Authors: Isaura Vieira, Mirella Corio, Maria Rosaria Perrini, Matteo Ruggeri

Internal reviewers: Hanan Bell, Marco Oradei, Michelle O'Neill, Patricia Harrington, Kristi Liiv

The studies selected and extracted from the basic literature search were analysed. Eight studies {1; 2; 3; 4; 5; 7; 8; 9} were found to be relevant to this question because they had a chapter dedicated to costs.

The majority of the studies that were found to be relevant did not present the unit costs by resource but instead provided only the total cost of the identified resource. Additionally, costs can vary from region to region and are not transferable to national HTA production.

Due to the limitations referred to in the domain introduction, the objective here is to prepare a rough description of the structure of an economic evaluation. It was not considered appropriate to present the unit costs for each resource identified.

Critical
Not
Vieira I et al. Result Card ECO3 In: Vieira I et al. Costs and economic evaluation In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 2 December 2022]. Available from: http://corehta.info/ViewCover.aspx?id=113

References